Sonnet Biotherapeutics Holdings Inc. - notizie pubblicate 171 - letture 3.447
SONNET BIOTHERAPEUTICS HOLDINGS INC.
Supplemental Prospectus - Form 424B3
Filed pursuant to rule 424(b)(3) registration no. 333-280705 prospectus 5,770,140 shares of common stock issuable upon exercise of outstanding warrants this prospectus relates to t ...
SONNET BIOTHERAPEUTICS HOLDINGS INC.
Registration Statement Specified Transactions Form S 3
As filed with the securities and exchange commission on july 5, 2024 registration no. 333- united states securities and exchange commission washington, d.c. 20549 form s-3 registra ...
SONNET BIOTHERAPEUTICS HOLDINGS INC.
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds Form 8 K
Sonnet biotherapeutics announces exercise of warrants for $3.4 million in gross proceeds princeton, n.j., june 20, 2024 (globe newswire) - sonnet biotherapeutics holdings, inc. (na ...
SONNET BIOTHERAPEUTICS HOLDINGS INC.
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
Sonnet biotherapeutics announces exercise of warrants for $3.4 million in gross proceeds download as pdfjune 20, 2024 8:30am edt princeton, n.j., june 20, 2024 (globe newswire) -- ...
SONNET BIOTHERAPEUTICS HOLDINGS INC.
Material Event Form 8 K
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer sonnet biotherapeuti ...
SONNET BIOTHERAPEUTICS HOLDINGS INC.
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON 1411 and SON 1400, Each Containing a Variant IL 18 Domain Form 8 K
Sonnet biotherapeutics announces the generation and characterization of two novel immunotherapeutic pipeline drug candidates, son-1411 and son-1400, each containing a variant il-18 ...
SONNET BIOTHERAPEUTICS HOLDINGS INC.
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON 1411 and SON 1400, Each Containing a Variant IL 18 Domain
Sonnet biotherapeutics announces the generation and characterization of two novel immunotherapeutic pipeline drug candidates, son-1411 and son-1400, each containing a variant il-18 ...
SONNET BIOTHERAPEUTICS HOLDINGS INC.
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
Sonnet biotherapeutics to present sb221 as a trial in progress at the asco 2024 annual meeting download as pdfmay 28, 2024 8:00am edt princeton, n.j., may 28, 2024 (globe newswire) ...
SONNET BIOTHERAPEUTICS HOLDINGS INC.
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
Sonnet biotherapeutics announces review of strategic alternatives download as pdfmay 22, 2024 8:33am edt princeton, nj / accesswire / may 22, 2024 / sonnet biotherapeutics holdings ...
SONNET BIOTHERAPEUTICS HOLDINGS INC.
Sonnet BioTherapeutics Announces Review of Strategic Alternatives - Form 8-K
Sonnet biotherapeutics announces review of strategic alternatives princeton, nj / accesswire / may 22, 2024 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) (the "company ...
SONNET BIOTHERAPEUTICS HOLDINGS INC.
Sonnet BioTherapeutics Announces Updated Clinical Data for SON 1010 as Monotherapy or Combined with an anti PD L1, along with an Increase in the Dose Escalation Target
The text version of this document is not available. you can access the original document here. attachments original link permalink disclaimer sonnet biotherapeutics holdings inc. p ...
SONNET BIOTHERAPEUTICS HOLDINGS INC.
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target - Form 8-K
Sonnet biotherapeutics announces updated clinical data for son-1010 as monotherapy or combined with an anti-pd-l1, along with an increase in the dose-escalation target ● the son- ...
SONNET BIOTHERAPEUTICS HOLDINGS INC.
Notice of Effectiveness - Form EFFECT
Notice of effectiveness united states securities and exchange commission washington, d.c. 20549 notice of effectiveness effectiveness date: may 16, 2024 4:00 p.m. form: s-1 cik: 00 ...
SONNET BIOTHERAPEUTICS HOLDINGS INC.
Supplemental Prospectus - Form 424B3
Filed pursuant to rule 424(b)(3) registration no. 333-279095 prospectus up to 5,000,000 shares of common stock this prospectus relates to the potential offer and sale from time to ...
SONNET BIOTHERAPEUTICS HOLDINGS INC.
Amendment to Initial Registration Statement - Form S-1/A
As filed with the securities and exchange commission on may 15, 2024 registration no. 333-279095 united states securities and exchange commission washington, d.c. 20549 amendment n ...
Per i consulenti finanziari
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti